Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Yong-Joon | - |
dc.contributor.author | Cho, Jae Young | - |
dc.contributor.author | You, Seng Chan | - |
dc.contributor.author | Lee, Yong-Ho | - |
dc.contributor.author | Yun, Kyeong Ho | - |
dc.contributor.author | Cho, Yun-Hyeong | - |
dc.contributor.author | Shin, Won-Yong | - |
dc.contributor.author | Im, Sang Wook | - |
dc.contributor.author | Kang, Woong Chol | - |
dc.contributor.author | Park, Yongwhi | - |
dc.contributor.author | Lee, Sung Yoon | - |
dc.contributor.author | Lee, Seung-Jun | - |
dc.contributor.author | Hong, Sung-Jin | - |
dc.contributor.author | Ahn, Chul-Min | - |
dc.contributor.author | Kim, Byeong-Keuk | - |
dc.contributor.author | Ko, Young-Guk | - |
dc.contributor.author | Choi, Donghoon | - |
dc.contributor.author | Hong, Myeong-Ki | - |
dc.contributor.author | Jang, Yangsoo | - |
dc.contributor.author | Kim, Jung-Sun | - |
dc.date.accessioned | 2023-04-01T03:40:56Z | - |
dc.date.available | 2023-04-01T03:40:56Z | - |
dc.date.created | 2023-01-18 | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 0195-668X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87407 | - |
dc.description.abstract | Aims This study evaluated the effect of moderate-intensity statin with ezetimibe combination therapy vs. high-intensity statin monotherapy among patients with diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD).Methods and results This was a pre-specified, stratified subgroup analysis of the DM cohort in the RACING trial. The primary outcome was a 3-year composite of cardiovascular death, major cardiovascular events, or non-fatal stroke. Among total patients, 1398 (37.0%) had DM at baseline. The incidence of the primary outcome was 10.0% and 11.3% among patients with DM randomized to ezetimibe combination therapy vs. high-intensity statin monotherapy (hazard ratio: 0.89; 95% confidence interval: 0.64-1.22; P = 0.460). Intolerance-related discontinuation or dose reduction of the study drug was observed in 5.2% and 8.7% of patients in each group, respectively (P = 0.014). LDL cholesterol levels < 70 mg/dL at 1, 2, and 3 years were observed in 81.0%, 83.1%, and 79.9% of patients in the ezetimibe combination therapy group, and 64.1%, 70.2%, and 66.8% of patients in the high-intensity statin monotherapy group (all P < 0.001). In the total population, no significant interactions were found between DM status and therapy regarding primary outcome, intolerance-related discontinuation or dose reduction, and the proportion of patients with LDL cholesterol levelsConclusion Ezetimibe combination therapy effects observed in the RACING trial population are preserved among patients with DM. This study supports moderate-intensity statin with ezetimibe combination therapy as a suitable alternative to high-intensity statins if the latter cannot be tolerated, or further reduction in LDL cholesterol is required among patients with DM and ASCVD. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.relation.isPartOf | EUROPEAN HEART JOURNAL | - |
dc.title | Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000899251600001 | - |
dc.identifier.doi | 10.1093/eurheartj/ehac709 | - |
dc.identifier.bibliographicCitation | EUROPEAN HEART JOURNAL, v.44, no.11, pp.972 - 983 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85150226079 | - |
dc.citation.endPage | 983 | - |
dc.citation.startPage | 972 | - |
dc.citation.title | EUROPEAN HEART JOURNAL | - |
dc.citation.volume | 44 | - |
dc.citation.number | 11 | - |
dc.contributor.affiliatedAuthor | Kang, Woong Chol | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Ezetimibe | - |
dc.subject.keywordAuthor | Statin | - |
dc.subject.keywordAuthor | Diabetes mellitus | - |
dc.subject.keywordAuthor | Atherosclerotic cardiovascular disease | - |
dc.subject.keywordPlus | END-POINTS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | ATORVASTATIN | - |
dc.subject.keywordPlus | DEFINITIONS | - |
dc.subject.keywordPlus | CHOLESTEROL | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | EVENTS | - |
dc.subject.keywordPlus | RISK | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.